Skip to main content

11.01.2025 | Original Research Article

Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study

verfasst von: Seo Young Sohn, Yun Jin Kim, Sungsoo Cho, Sung Woo Cho

Erschienen in: American Journal of Cardiovascular Drugs

Einloggen, um Zugang zu erhalten

Abstract

Background

Amiodarone is an effective anti-arrhythmic drug; however, it is frequently associated with thyroid dysfunction. The aim of this study was to investigate the incidence and risk factor of amiodarone-induced dysfunction in an iodine-sufficient area.

Methods

This retrospective cohort study included 27,023 consecutive patients treated with amiodarone for arrhythmia, using the Korean National Health Insurance database. A Cox regression analysis was performed to determine independent risk factors for amiodarone-induced thyroid dysfunction.

Results

During a mean follow-up period of 6.4 years, 1326 (4.9%) patients developed thyrotoxicosis and 3121 (11.5%) developed hypothyroidism. The incidence rate of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) was 6.92 and 17.1 per 1000 person-years, respectively. In the multivariate analysis, chronic kidney disease (CKD) [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.06–1.99], and Hashimoto’s thyroiditis (HR 2.00, 95% CI 1.31–3.07) were associated with AIT, while female sex (HR 1.22, 95% CI 1.14–1.32), diabetes (HR 1.14, 95% CI 1.06–1.24), CKD (HR 1.18, 95% CI 1.05–1.34), and Hashimoto’s thyroiditis (HR 2.26, 95% CI 1.66–3.09) were associated with AIH.

Conclusions

The incidence of AIH was higher compared with AIT in an area with sufficient iodine intake. Several potential risk factors for AIT and AIH were identified. When amiodarone treatment is considered for patients, particularly those at a high risk of thyroid dysfunction, it is warranted to perform regular thyroid function assessments.
Literatur
1.
2.
Zurück zum Zitat Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166(7):719–28.CrossRefPubMed Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, Mahé I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166(7):719–28.CrossRefPubMed
3.
Zurück zum Zitat Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4(9):1250–9.CrossRefPubMed Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007;4(9):1250–9.CrossRefPubMed
4.
Zurück zum Zitat Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139–52.CrossRefPubMedPubMedCentral Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139–52.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 1987;26(1–4):158–71.CrossRefPubMed Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 1987;26(1–4):158–71.CrossRefPubMed
7.
Zurück zum Zitat Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6(1):34–41.CrossRefPubMed Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6(1):34–41.CrossRefPubMed
8.
Zurück zum Zitat Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171(3):363–8.CrossRefPubMed Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171(3):363–8.CrossRefPubMed
9.
Zurück zum Zitat Ylli D, Wartofsky L, Burman KD. Evaluation and treatment of amiodarone-induced thyroid disorders. J Clin Endocrinol Metab. 2021;106(1):226–36.CrossRefPubMed Ylli D, Wartofsky L, Burman KD. Evaluation and treatment of amiodarone-induced thyroid disorders. J Clin Endocrinol Metab. 2021;106(1):226–36.CrossRefPubMed
10.
Zurück zum Zitat Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984;101(1):28–34.CrossRefPubMed Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984;101(1):28–34.CrossRefPubMed
11.
Zurück zum Zitat Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011;75(3):388–94.CrossRefPubMed Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011;75(3):388–94.CrossRefPubMed
12.
Zurück zum Zitat Uchida T, Kasai T, Takagi A, Sekita G, Komiya K, Takeno K, et al. Prevalence of amiodarone-induced thyrotoxicosis and associated risk factors in Japanese patients. Int J Endocrinol. 2014;2014: 534904.CrossRefPubMedPubMedCentral Uchida T, Kasai T, Takagi A, Sekita G, Komiya K, Takeno K, et al. Prevalence of amiodarone-induced thyrotoxicosis and associated risk factors in Japanese patients. Int J Endocrinol. 2014;2014: 534904.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Stan MN, Ammash NM, Warnes CA, Brennan MD, Thapa P, Nannenga MR, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease—a cohort study. Int J Cardiol. 2013;167(3):821–6.CrossRefPubMed Stan MN, Ammash NM, Warnes CA, Brennan MD, Thapa P, Nannenga MR, et al. Body mass index and the development of amiodarone-induced thyrotoxicosis in adults with congenital heart disease—a cohort study. Int J Cardiol. 2013;167(3):821–6.CrossRefPubMed
14.
Zurück zum Zitat Sidhu J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK. QJM. 2003;96(12):949–50.CrossRefPubMed Sidhu J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK. QJM. 2003;96(12):949–50.CrossRefPubMed
15.
Zurück zum Zitat Zosin I, Balaş M. Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol Pol. 2012;63(1):2–9.PubMed Zosin I, Balaş M. Amiodarone-induced thyroid dysfunction in an iodine-replete area: epidemiological and clinical data. Endokrynol Pol. 2012;63(1):2–9.PubMed
16.
Zurück zum Zitat Lee KF, Lee KM, Fung TT. Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population. Hong Kong Med J. 2010;16(6):434–9.PubMed Lee KF, Lee KM, Fung TT. Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population. Hong Kong Med J. 2010;16(6):434–9.PubMed
17.
Zurück zum Zitat Huang CJ, Chen PJ, Chang JW, Huang DF, Chang SL, Chen SA, et al. Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study. Int J Clin Pharm. 2014;36(2):405–11.CrossRefPubMed Huang CJ, Chen PJ, Chang JW, Huang DF, Chang SL, Chen SA, et al. Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study. Int J Clin Pharm. 2014;36(2):405–11.CrossRefPubMed
18.
Zurück zum Zitat Yiu KH, Jim MH, Siu CW, Lee CH, Yuen M, Mok M, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009;94(1):109–14.CrossRefPubMed Yiu KH, Jim MH, Siu CW, Lee CH, Yuen M, Mok M, et al. Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. J Clin Endocrinol Metab. 2009;94(1):109–14.CrossRefPubMed
19.
Zurück zum Zitat Conen D, Melly L, Kaufmann C, Bilz S, Ammann P, Schaer B, et al. Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. J Am Coll Cardiol. 2007;49(24):2350–5.CrossRefPubMed Conen D, Melly L, Kaufmann C, Bilz S, Ammann P, Schaer B, et al. Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. J Am Coll Cardiol. 2007;49(24):2350–5.CrossRefPubMed
20.
Zurück zum Zitat Sohn SY, Seo GH, Chung JH. Risk of all-cause mortality in levothyroxine-treated hypothyroid patients: a nationwide Korean cohort study. Front Endocrinol (Lausanne). 2021;12: 680647.CrossRefPubMedPubMedCentral Sohn SY, Seo GH, Chung JH. Risk of all-cause mortality in levothyroxine-treated hypothyroid patients: a nationwide Korean cohort study. Front Endocrinol (Lausanne). 2021;12: 680647.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Kornelius E, Chiou JY, Yang YS, Peng CH, Lai YR, Huang CN. Iodinated contrast media increased the risk of thyroid dysfunction: a 6-year retrospective cohort study. J Clin Endocrinol Metab. 2015;100(9):3372–9.CrossRefPubMed Kornelius E, Chiou JY, Yang YS, Peng CH, Lai YR, Huang CN. Iodinated contrast media increased the risk of thyroid dysfunction: a 6-year retrospective cohort study. J Clin Endocrinol Metab. 2015;100(9):3372–9.CrossRefPubMed
22.
Zurück zum Zitat Thvilum M, Brandt F, Lillevang-Johansen M, Folkestad L, Brix TH, Hegedus L. Increased risk of dementia in hypothyroidism: a Danish nationwide register-based study. Clin Endocrinol (Oxf). 2021;94(6):1017–24.CrossRefPubMed Thvilum M, Brandt F, Lillevang-Johansen M, Folkestad L, Brix TH, Hegedus L. Increased risk of dementia in hypothyroidism: a Danish nationwide register-based study. Clin Endocrinol (Oxf). 2021;94(6):1017–24.CrossRefPubMed
23.
Zurück zum Zitat Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation. 1999;100(2):149–54.CrossRefPubMed Thorne SA, Barnes I, Cullinan P, Somerville J. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation. 1999;100(2):149–54.CrossRefPubMed
24.
Zurück zum Zitat Park SY, Kim HI, Oh HK, Kim TH, Jang HW, Chung JH, et al. Age- and gender-specific reference intervals of TSH and free T4 in an iodine-replete area: data from Korean National Health and Nutrition Examination Survey IV (2013–2015). PLoS One. 2018;13(2): e0190738.CrossRefPubMedPubMedCentral Park SY, Kim HI, Oh HK, Kim TH, Jang HW, Chung JH, et al. Age- and gender-specific reference intervals of TSH and free T4 in an iodine-replete area: data from Korean National Health and Nutrition Examination Survey IV (2013–2015). PLoS One. 2018;13(2): e0190738.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91(5):507–11.CrossRefPubMed Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med. 1991;91(5):507–11.CrossRefPubMed
26.
Zurück zum Zitat Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant. 2004;19(5):1190–7.CrossRefPubMed Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant. 2004;19(5):1190–7.CrossRefPubMed
28.
Zurück zum Zitat Ali SA, Ersboll M, Vinding NE, Butt JH, Rorth R, Selmer C, et al. Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study. Europace. 2023;25(2):291–9.CrossRefPubMed Ali SA, Ersboll M, Vinding NE, Butt JH, Rorth R, Selmer C, et al. Incidence of thyroid dysfunction following initiation of amiodarone treatment in patients with and without heart failure: a nationwide cohort study. Europace. 2023;25(2):291–9.CrossRefPubMed
29.
Zurück zum Zitat Díez JJ, Iglesias P. An analysis of the relative risk for hypothyroidism in patients with type 2 diabetes. Diabet Med. 2012;29(12):1510–4.CrossRefPubMed Díez JJ, Iglesias P. An analysis of the relative risk for hypothyroidism in patients with type 2 diabetes. Diabet Med. 2012;29(12):1510–4.CrossRefPubMed
30.
Zurück zum Zitat Kwon H, Jung JH, Han KD, Park YG, Cho JH, Lee DY, et al. Prevalence and annual incidence of thyroid disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study. Endocrinol Metab (Seoul). 2018;33(2):260–7.CrossRefPubMedPubMedCentral Kwon H, Jung JH, Han KD, Park YG, Cho JH, Lee DY, et al. Prevalence and annual incidence of thyroid disease in Korea from 2006 to 2015: A Nationwide Population-Based Cohort Study. Endocrinol Metab (Seoul). 2018;33(2):260–7.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefPubMed Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefPubMed
32.
Zurück zum Zitat Huang CJ, Tseng CL, Chu CH, Huang DF, Huang CC, Lin LY. Adherence to guidelines in monitoring amiodarone-induced thyroid dysfunction. J Eval Clin Pract. 2017;23(1):108–13.CrossRefPubMed Huang CJ, Tseng CL, Chu CH, Huang DF, Huang CC, Lin LY. Adherence to guidelines in monitoring amiodarone-induced thyroid dysfunction. J Eval Clin Pract. 2017;23(1):108–13.CrossRefPubMed
Metadaten
Titel
Incidence and Risk Factors for Amiodarone-Induced Thyroid Dysfunction: A Nationwide Retrospective Cohort Study
verfasst von
Seo Young Sohn
Yun Jin Kim
Sungsoo Cho
Sung Woo Cho
Publikationsdatum
11.01.2025
Verlag
Springer International Publishing
Erschienen in
American Journal of Cardiovascular Drugs
Print ISSN: 1175-3277
Elektronische ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-024-00717-6

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Kardiologie

Blutdruck am Belastungsende zeigt kardiovaskuläres Risiko

Diverse Blutdruckparameter während der Ergometrie sind schon auf ihre Aussagekraft, Mortalität und kardiovaskuläres Risiko betreffend, hin abgeklopft worden. Nun hat auch das Druckverhalten am Ende der Belastung im Fokus einer Studie gestanden.

Neue US-Leitlinie zum Management bei akutem Koronarsyndrom

In den USA ist die Leitlinie zum Management bei akutem Koronarsyndrom aktualisiert worden. In Europa erfolgte das neueste Guideline-Update dazu bereits 2023. Gehen beide Leitlinien konform oder gibt es nennenswerte Differenzen? 

Mechanische Herzklappe beschert jüngeren Betroffenen längeres Leben

Patienten und Patientinnen bevorzugen bioprothetische Herzklappen gegenüber mechanischen Klappenprothesen. Diese Wahl könnte sich zumindest für jüngere Patienten nachteilig auswirken: Ihnen bietet eine mechanische Klappe anscheinend einen Überlebensvorteil.

Lp(a) wird zu selten gemessen

Laut europäischer Dyslipidämie-Leitlinie sollte die Bestimmung der Serumkonzentration von Lipoprotein (a) mindestens einmal im Leben jedes Erwachsenen erwogen werden. Tatsächlich wird die Messung selbst kardiovaskulär gefährdeten Personen nur selten zuteil.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.